Key result
SGLT2 inhibitors may correct dilutional hyponatremia in HF via improved free-water clearance over conventional diuretics.
Why the study?
Conventional management of hyponatremia in HF, such as fluid restriction and loop diuretics, often only temporarily corrects sodium imbalance and may worsen maladaptive neurohormonal responses, creating a need to evaluate whether SGLT2 inhibitors offer benefits beyond standard management for improving sodium balance.
Do sodium-glucose cotransporter-2 inhibitors improve serum sodium balance and overall clinical outcomes compared to conventional management in patients with heart failure and hyponatremia?
Do sodium-glucose cotransporter-2 inhibitors improve serum sodium balance and overall clinical outcomes compared to conventional management in patients with heart failure and hyponatremia?
This narrative review highlights the potential of SGLT2 inhibitors to correct dilutional hyponatremia in heart failure via osmotic diuresis and improved free-water clearance, offering benefits beyond conventional diuretic therapy.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors may offer a preferable option for hyponatremia correction in heart failure; extends their role to electrolyte management beyond cardiovascular outcomes.
Heart failure (HF) patients frequently have aberrant serum sodium levels, especially hyponatremia, which is closely linked to poor clinical outcomes, such as greater morbidity, longer hospital stays, and higher death rates. The renin–angiotensin–aldosterone system, arginine vasopressin, decreased renal perfusion, and neurohormonal activation are the main causes of the complex pathophysiology of hyponatremia in HF. The cornerstone of treatment is still conventional management techniques such as fluid restriction and loop diuretics, although these methods frequently only temporarily correct sodium imbalance and may even exacerbate maladaptive neurohormonal reactions. Therefore, it is necessary to develop effective therapeutic approaches that can address the progression of HF as well as related electrolyte imbalances. Regardless of diabetes status, sodium–glucose cotransporter-2 (SGLT2) inhibitors have shown notable reductions in hospitalization and cardiovascular mortality, making them a crucial part of guideline-directed therapy for HF. A growing body of research indicates that SGLT2 inhibitors may have positive effects on serum sodium balance in addition to their well-established cardioprotective and renoprotective advantages. These medications may help correct dilutional hyponatremia while preserving electrolyte balance more successfully than conventional diuretic therapy through processes such as osmotic diuresis, improved free-water clearance, and modulation of renal sodium handling. This review objectively assesses the available clinical data on the effect of SGLT2 inhibitors on serum sodium levels and investigates the underlying pathophysiological mechanisms of sodium abnormalities in HF. In addition, it investigates if these drugs’ therapeutic benefits go beyond standard management techniques in terms of enhancing sodium balance and overall clinical outcomes in HF patients.
No takes yet. Share an insight, caveat, or question.
George et al. (2026) conducted a review in Heart failure with serum sodium abnormalities (hyponatremia). Sodium-glucose cotransporter-2 (SGLT2) inhibitors vs. Conventional management techniques (fluid restriction and loop diuretics) was evaluated on Serum sodium balance and overall clinical outcomes in heart failure. SGLT2 inhibitors may correct dilutional hyponatremia and preserve electrolyte balance in heart failure via osmotic diuresis and improved free-water clearance compared to conventional diuretics.
Synapse has enriched 10 related papers. Consider them for comparative context: